USD10
FATE Shares
About Fate TherapeuticsFate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
USD10
FATE Shares
About Fate TherapeuticsFate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$320.77M
OPEN PRICE
$2.53
LOW (1Y)
$0.6611
HIGH (1Y)
$1.94
LOW (24H)
$2.48
HIGH (24H)
$2.88
VOLUME (24H)
$4.02M
80.28%
Price history
Time | Price | Change |
|---|---|---|
Today | $2.53 | |
1 Day | $2.84 | |
1 Week | $2.43 | |
1 Month | $2.93 | |
1 Year | $0.9357 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.